

DONCASTER ROYAL INFIRMARY
ARMTHORPE ROAD
DONCASTER
DN2 5LT

17th August 2023

FOI Request: Treatment of inflammatory diseases

Dear Freedom of Information Officer,

I am conducting analysis on drugs used to treat inflammatory diseases and kindly request your help.

I would be grateful if you could tell me how many patients were treated by individual drug for Crohn's Disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis in three months from the start of May 2023 to the end of July 2023 (or the latest available 3 months).

I have provided a grid of drug names and disease names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

If data is unavailable for question 1 it would be helpful if you can provide the information at a department level (question 2).

Thank you in advance.

Yours faithfully,

Andrew Wiles

Appendix A

Q1 – How many patients were treated with the following drugs for the following diseases in the 3 months between the start of May 2023 and the end of July 2023?

Please use the latest available 3 months if May to July is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab (Humira)						
Adalimumab (Biosimilars)						
Apremilast						
Bimekizumab						
Brodalumab						
Certolizumab Pegol						
Deucravacitinib						
Etanercept (Enbrel)						
Etanercept (Biosimilars)						
Guselkumab						
Infliximab (Remicade)						
Infliximab (Biosimilars)						
Ixekizumab						
Risankizumab						
Secukinumab						
Tildrakizumab						
Ustekinumab						
Upadacitinib						
Vedolizumab						
Filgotinib						
Golimumab						
Mirikizumab						
Ozanimod						
Tofacitinib						
Abatacept						
Baricitinib						
Rituximab						
Sarilumab						
Tocilizumab						

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Q2 – How many patients were treated with the following drugs from the following departments (for any disease) in the 3 months between the start of May 2023 and the end of July 2023?

Please use the latest available 3 months if May to July is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)	1	15	28
Adalimumab (Biosimilars)	22	113	444
Apremilast	35	0	0
Bimekizumab	0	0	0
Brodalumab	7	0	0
Certolizumab Pegol	1	0	22
Deucravacitinib	0	0	0
Etanercept (Enbrel)	0	0	30
Etanercept (Biosimilars)	0	0	187
Guselkumab	36	0	2
Infliximab (Remicade)	0	0	7
Infliximab (Biosimilars)	0	210	25
Ixekizumab	7	0	40
Risankizumab	0	0	0
Secukinumab	44	0	47
Tildrakizumab	0	0	0
Ustekinumab	12	101	4
Upadacitinib	0	1	25
Vedolizumab	0	82	0
Filgotinib	0	0	49
Golimumab	0	3	45
Mirikizumab	0	0	0
Ozanimod	0	0	0
Tofacitinib	0	0	6
Abatacept	0	0	15
Baricitinib	2	0	57
Rituximab	0	0	23
Sarilumab	0	0	6
Tocilizumab	1	0	37

